Analysts forecast that Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) will post ($0.37) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Galmed Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.60). Galmed Pharmaceuticals reported earnings of ($0.19) per share during the same quarter last year, which indicates a negative year over year growth rate of 94.7%. The business is expected to announce its next earnings results on Wednesday, March 11th.
According to Zacks, analysts expect that Galmed Pharmaceuticals will report full year earnings of ($0.93) per share for the current fiscal year, with EPS estimates ranging from ($1.15) to ($0.82). For the next financial year, analysts expect that the company will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.69) to ($0.88). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Galmed Pharmaceuticals.
Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.11.
Shares of GLMD traded down $0.16 during mid-day trading on Monday, reaching $5.61. The company had a trading volume of 58,096 shares, compared to its average volume of 86,000. The company’s 50 day simple moving average is $6.05 and its 200 day simple moving average is $5.25. Galmed Pharmaceuticals has a 1-year low of $3.42 and a 1-year high of $9.37. The company has a debt-to-equity ratio of 0.01, a quick ratio of 22.78 and a current ratio of 22.78. The company has a market capitalization of $121.29 million, a price-to-earnings ratio of -7.29 and a beta of 2.96.
A number of large investors have recently bought and sold shares of the stock. Ibex Investors LLC boosted its position in Galmed Pharmaceuticals by 18.3% during the 3rd quarter. Ibex Investors LLC now owns 955,105 shares of the biopharmaceutical company’s stock worth $4,565,000 after buying an additional 147,705 shares during the period. Phoenix Holdings Ltd. acquired a new stake in Galmed Pharmaceuticals during the 3rd quarter worth approximately $115,000. Morgan Stanley boosted its position in Galmed Pharmaceuticals by 132.1% during the 2nd quarter. Morgan Stanley now owns 14,783 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 8,414 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Galmed Pharmaceuticals by 796.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,207 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 4,626 shares during the period. Institutional investors and hedge funds own 34.54% of the company’s stock.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Further Reading: Market Indexes
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.